Patent application number | Description | Published |
20080274446 | Cryopreserved human neuronal cultures - Cryopreserved cultures of post-mitotic neuronal or neural-like cells are provided having a viability after thaw of greater than 10%, typically greater than 50%. Once thawed, the cells are capable of further differentiation. In one embodiment, less than 20% of the cryopreserved cells are self-proliferating cells. The cells can be provided in a kit including a container of the cryopreserved neuronal or neural-like cells, optionally including additional cell culture reagents and materials. Method for preparing the cryopreserved neuronal or neural-like cells derived from embryonic stem cells, preferably human embryonic stem cells, are also provided. | 11-06-2008 |
20090092588 | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. | 04-09-2009 |
20100184212 | HUMAN EMBRYONIC STEM CELL DERIVED MESODERM-LIKE EPITHELIUM TRANSITIONS TO MESENCHYMAL PROGENITOR CELLS - Human embryonic stem cells (hESC) have the potential to produce all of the cells in the body. They are also able to self-renew indefinitely, sparking the hope they could be used as a source for large scale production of therapeutic cell lines. The present invention relates to a monolayer differentiation culture system that induces hESC (WA09 and BG01) to form epithelial sheets with mesodermal gene expression patterns (BMP4, RUNX1, GAT A4). These E-cadherin+ CD90lovv cells then undergo apparent epithelial-mesenchymal transformation (EMT) for the derivation of mesenchymal progenitor cells (hES-MC) that by flow cytometry are negative for hematopoietic (CD34, CD45 and CD 133) and endothelial (CD31 and CD 146) markers, but positive for markers associated with mesenchymal stem cells (MSC) (CD73, CD90, CD105 and CD166). To determine their functionality, we tested their capacity to produce the three lineages commonly associated with MSC and found they could form osteogenic and chondrogenic, but not adipogenic lineages. The derived hES-MC were able to remodel and contract collagen I lattice constructs to an equivalent degree as keloid fibroblast control cells and were induced to express αSMA when exposed to TGF-β1, but not PDGF-B. This data suggests the derived hES-MC cells are multipotent cells with potential uses in tissue engineering/regenerative medicine and for providing a highly reproducible cell source for adult-like progenitor cells. | 07-22-2010 |
20110044954 | Methods of producing germ-like cells and related therapies - The present invention relates to methods of producing germ-like cells (GLCs) from embryonic stem cells and induced pluripotent stem cells, GLCs produced by such methods, gametes derived from such GLCs, pharmaceutical compositions and kits containing such GLCs, screens that use GLCs to identify agents useful in enhancing mammalian reproductive health, and methods of treatment that use GLCs to enhance mammalian reproductive health. | 02-24-2011 |
Patent application number | Description | Published |
20110277049 | PRODUCTION OF CLONED OFFSPRING FROM COOLED CARCASSES - Genetic material is derived from animals post-mortem, and used in nuclear transfer processes to produce cloned embryos and live cloned animals having genetic make-ups identical to the post mortem animals. The method has particular applicability to the management and breeding of livestock, to the production of animals having desired genetic traits, and to the integration of those genetic traits into selective breeding operations. | 11-10-2011 |
20130007904 | PRODUCTION OF CLONED OFFSPRING FROM COOLED CARCASSES - Genetic material is derived from animals post-mortem, and used in nuclear transfer processes to produce cloned embryos and live cloned animals having genetic make-ups identical to the post mortem animals. The method has particular applicability to the management and breeding of livestock, to the production of animals having desired genetic traits, and to the integration of those genetic traits into selective breeding operations. | 01-03-2013 |
20140363467 | AVIAN INDUCED PLURIPOTENT STEM CELLS AND THEIR USE - The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring. | 12-11-2014 |
20150320833 | OSSIFICATION-INDUCING COMPOSITIONS AND METHODS OF USE THEREOF - Mesenchymal stem cells (MSCs) and uses thereof are provided. MSCs for inducing ossification and enhancing bone and/qr cartilage repair in a patient in need thereof are also provided. The method and compositions combine MSCs, at least one bone regeneration protein, such as bone morphogenetic protein (e.g. BMP-2), optionally in combination with additional cell growth factors including the components of a cell growth medium, further in combination with a biomaterial for delivery of the cells to the repair site in the patient are also provided. | 11-12-2015 |